L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
HCS PHARMA développe et commercialise des produits de culture cellulaire 3D basés sur sa technologie disruptive, exclusive et propriétaire BIOMIMESYS, hydrosquelette qui permet de reproduire la matrice extracellulaire de façon organe-spécifique.
Lille, Hauts-de-France, France
Envoyer un message
We are pleased to announce that HCS Pharma secured 20 Million EUR capital commitment from GEM group following the public listing of the company shares on a European stock exchange. We are under the IPO process that we will finalize in the next coming months. The proceeds of IPO with GEM commitment will be used to accelerate the development of the range of BIOMIMESYS® products and their commercialization in the global market.
If you want to better known what we are doing now in HCS Pharma and if your native language is korean, you can discover it with this article : HCS Pharma, 생리학적으로 중요한 3d Cell Model의 Phenotypic Screening에 ImageXpress Micro Confocal 시스템 사용
We explain in the text how we use the amazing confocal automatic microscopes from Molecular Devices and why we have chosen to focus our research in 3D biological models. Spoiler alert : it’s much more close to real human body than a 2D mouse
Many thanks to the Molecular Devices korean team for the translation of the article.
We are very please to welcome two new members in our scientific advisory board.
Dr Vincent Senez from the Institute of Cancer Research of Lille (IRCL) is specialized in microfluidics and lab-on-a-chip technologies. We work together on several projects to implement a specific version of our BIOMIMESYS® hydroscaffold to create the next generation organ-on-the-chip technology.
Dr Isabelle Van Seuningen is the director of the Canther laboratory and the Lille Cancer Institute ONCOLille. We have the ambition to develop the international recognition of cancer research in Lille through multi disciplinary projects.
In 2020, HCS Pharma has been selected to be part of the InvestHorizon coaching program. In this coaching program, 500 investors challenged over 1,000 selected tech entrepreneurs over multiple sessions to level up their investment and growth.
During this coaching program, we have participated in several events to be challanged by experts and investors. We are proud to received a new label during this coaching program: Top Health Companies - InvestHorizon Pitching Forum and finally, we are proud to have been selected to be part of the Tech Tour Future 21 event this year.
During this event, 48 starp-up from health has been selected (4 deeptech, 29 digital health, 7 Medtech and 8 pharma & biotech). The presence of a majority of startups in digital health reflects the majority of investments made by European investors.
This event was amazing. I was able to pitch in front of 500 investors: https://hcs-pharma.com/techtour-2021-presention-hcs-pharma/. I had more than 15 BtoB meetings.
3D cell culture systems have recently as promising tools for reproducing the cellular environment and the organization of tissues/organs, where cells are connected to each other and to the surrounding extracellular matrix (ECM). Join us for this webinar to know more about BIOMIMESYS® technology, our 3D cell culture system designed for the physiologically-relevant culture of liver, brain, adipose tissue, and cancer cells in dedicated BIOMIMESYS® hydroscaffolds. Each matrix is characterized by its specific composition and stiffness, to be in accordance with in vivo conditions.
Débute le 08/2014
HCS Pharma founded by Nathalie MAUBON as a CRO
fund raising with FINOVAM & NFA: seed
New site with 250 m² of space with: - 2 cell culture labs - 1 automation lab with 1 robotic platform